Holen Sie sich die Stockscreener-App
45.95
2.45%
1.10
Handel nachbörslich:
45.88
-0.07
-0.15%
Schlusskurs vom Vortag:
$44.85
Offen:
$45.22
24-Stunden-Volumen:
932.28K
Relative Volume:
1.15
Marktkapitalisierung:
$2.36B
Einnahmen:
$1.28B
Nettoeinkommen (Verlust:
$-222.15M
KGV:
-11.23
EPS:
-4.09
Netto-Cashflow:
$145.52M
1W Leistung:
+6.24%
1M Leistung:
+30.69%
6M Leistung:
-7.56%
1J Leistung:
-12.97%
1-Tages-Spanne:
$45.22
$46.11
1-Wochen-Bereich:
$42.79
$46.11
52-Wochen-Spanne:
$32.48
$57.35
Livanova Plc Stock (LIVN) Company Profile
Firmenname
Livanova Plc
Sektor
Branche
Telefon
4402033250662
Adresse
20 EASTBOURNE TERRACE, LONDON
Vergleichen Sie LIVN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LIVN
Livanova Plc
|
45.95 | 2.36B | 1.28B | -222.15M | 145.52M | -4.09 |
|
ABT
Abbott Laboratories
|
133.58 | 232.41B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
102.09 | 155.73B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
383.89 | 146.23B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
87.44 | 106.37B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
77.52 | 45.88B | 5.54B | 4.18B | 623.10M | 7.00 |
Livanova Plc Stock (LIVN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-20 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-02-26 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2024-10-04 | Eingeleitet | Goldman | Buy |
| 2024-09-17 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2024-03-20 | Bestätigt | Needham | Buy |
| 2024-02-20 | Hochstufung | Mizuho | Neutral → Buy |
| 2023-09-06 | Eingeleitet | HSBC Securities | Hold |
| 2023-07-19 | Eingeleitet | Robert W. Baird | Neutral |
| 2023-04-14 | Eingeleitet | Mizuho | Neutral |
| 2022-12-21 | Eingeleitet | Barclays | Equal Weight |
| 2022-04-06 | Eingeleitet | Wolfe Research | Outperform |
| 2022-02-24 | Hochstufung | UBS | Neutral → Buy |
| 2021-12-03 | Eingeleitet | Goldman | Buy |
| 2021-08-20 | Bestätigt | Needham | Buy |
| 2021-07-20 | Hochstufung | Needham | Hold → Buy |
| 2021-03-03 | Herabstufung | Berenberg | Buy → Hold |
| 2021-01-05 | Herabstufung | Needham | Buy → Hold |
| 2020-09-02 | Eingeleitet | Robert W. Baird | Outperform |
| 2020-06-26 | Bestätigt | Needham | Buy |
| 2019-10-30 | Bestätigt | Needham | Buy |
| 2019-02-28 | Bestätigt | Needham | Buy |
| 2018-11-28 | Eingeleitet | UBS | Neutral |
| 2018-08-02 | Bestätigt | Needham | Buy |
| 2018-06-08 | Eingeleitet | Stifel | Buy |
| 2018-05-31 | Bestätigt | Needham | Buy |
| 2018-02-28 | Bestätigt | Needham | Buy |
Alle ansehen
Livanova Plc Aktie (LIVN) Neueste Nachrichten
LivaNova completes epilepsy treatment study of VNS Therapy - Medical Device Network
LivaNova Announces CORE-VNS 24-Month Data Show Adjunctive VNS Therapy is Associated with Substantial Reductions in Generalized Tonic-Clonic Seizures in People with Drug-Resistant Epilepsy - BioSpace
LivaNova at Jefferies Conference: Strategic Growth and Challenges - Investing.com
LivaNova at Jefferies Conference: Strategic Growth and Challenges By Investing.com - Investing.com UK
Artificial Heart Lung Machines Market Projected to Witness - openPR.com
LIVN Reports Promising Outcomes in Drug-Resistant Epilepsy Study - GuruFocus
LivaNova reports positive VNS Therapy study results for epilepsy - Investing.com
CORE-VNS Study Further Validates Effectiveness of LivaNova's VNS Therapy on Severe Focal Seizures in Both Children and Adults with Drug-Resistant Epilepsy | LIVN Stock News - GuruFocus
LivaNova reports positive VNS Therapy study results for epilepsy By Investing.com - Investing.com UK
LivaNova Announces CORE-VNS 24-Month Data Show Adjunctive VNS Therapy is Associated with Substantial Reductions in Generalized Tonic-Clonic Seizures in People with Drug-Resistant Epilepsy | LIVN Stock - GuruFocus
LivaNova plc (LIVN) completes CORE-VNS study - StreetInsider
VNS therapy shows sustained seizure reduction in study - Investing.com
CORE-VNS Study Further Validates Effectiveness of LivaNova’s VNS Therapy on Severe Focal Seizures in Both Children and Adults with Drug-Resistant Epilepsy - The Joplin Globe
VNS therapy shows sustained seizure reduction in study By Investing.com - Investing.com UK
LivaNova (LIVN) Announces CORE-VNS 24-Month Data Show Adjunctive VNS Therapy is Associated with Substantial Reductions in Generalized Tonic-Clonic Seizures in People with Drug-Resistant Epilepsy - StreetInsider
LivaNova seeks Medicare coverage reconsideration for VNS Therapy By Investing.com - Investing.com South Africa
LivaNova wants CMS to reconsider neuromod for treating depression - MassDevice
Bioelectronic Medicine Market Research Report 2025 Featuring Key PlayersMedtronic, Abbott, Boston Scientific, Cochlear, LivaNova, Soterix Medical, Bioinduction, GiMer Medical, CEFALY, BioControl - GlobeNewswire
LivaNova Seeks Reconsideration of National Medicare Coverage for VNS Depression Treatment - marketscreener.com
LivaNova Initiates Process with U.S. Centers for Medicare and Medicaid Services for Reconsideration of National Coverage for VNS Therapy for Treatment-Resistant Depression - marketscreener.com
LivaNova Initiates Process with U.S. Centers for Medicare and Me - GuruFocus
LivaNova (LIVN) Seeks Expanded Medicare Coverage for VNS Therapy | LIVN Stock News - GuruFocus
LivaNova seeks Medicare coverage reconsideration for VNS Therapy - Investing.com India
LivaNova (LIVN) Initiates Process with U.S. Centers for Medicare and Medicaid Services for Reconsideration of National Coverage for VNS Therapy for Treatment-Resistant Depression - StreetInsider
LivaNova Announces 12-month Data from OSPREY Study - Medical Product Outsourcing
Vagus Nerve Stimulation (VNS) Market Poised for Breakthrough Growth: From $488.5M in 2022 to $836.1M by 2032 - openPR.com
LivaNova PLC (NASDAQ:LIVN) Receives Average Recommendation of “Buy” from Analysts - Defense World
Electroceuticals Market Generated Opportunities, Future - openPR.com
LivaNova’s SWOT analysis: medical device firm’s stock faces growth hurdles By Investing.com - Investing.com India
LivaNova’s SWOT analysis: medical device firm’s stock faces growth hurdles - Investing.com Australia
LivaNova's SWOT analysis: medical device firm's stock faces growth hurdles - Investing.com
(LIVN) Technical Data - news.stocktradersdaily.com
LivaNova PLC (NASDAQ:LIVN) Shares Acquired by Deutsche Bank AG - Defense World
LivaNova faces $360M liability after court ruling By Investing.com - Investing.com South Africa
LivaNova faces $360M liability after court ruling - Investing.com India
LivaNova (NASDAQ:LIVN) Raised to Outperform at Wolfe Research - Defense World
LivaNova Faces Legal Dispute Over Environmental Liabilities - TipRanks
Wolfe Research Upgrades LivaNova (LIVN) - Nasdaq
LivaNova (LIVN) Receives Upgrade to "Outperform" by Wolfe Research | LIVN Stock News - GuruFocus
Wolfe Research lifts Livanova stock rating, sets $60 target By Investing.com - Investing.com Nigeria
LivaNova (LIVN) Upgraded by Wolfe Research with a Positive Outlo - GuruFocus
LivaNova (LIVN) Upgraded by Wolfe Research with a Positive Outlook | LIVN Stock News - GuruFocus
LivaNova (LIVN) Receives Upgrade to "Outperform" by Wolfe Resear - GuruFocus
Bank of America Corp DE Sells 94,006 Shares of LivaNova PLC (NASDAQ:LIVN) - Defense World
LivaNova PLC (NASDAQ:LIVN) Shares Bought by BNP Paribas Financial Markets - Defense World
Combined Companies Sorin and Cyberonics Will Be Renamed LivaNova - Medical Product Outsourcing
LivaNova to Present at the Jefferies Global Healthcare Conference - The Joplin Globe
LIVN Stock Rating Reiterated at 'Buy' by Needham Analyst | LIVN - GuruFocus
LivaNova PLC (NASDAQ:LIVN) Q1 2025 Earnings Call Transcript - Insider Monkey
How to Take Advantage of moves in (LIVN) - news.stocktradersdaily.com
LivaNova PLC: Strong Growth Amidst Challenges in Earnings Call - TipRanks
Finanzdaten der Livanova Plc-Aktie (LIVN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Livanova Plc-Aktie (LIVN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Makatsaria Vladimir | Chief Executive Officer |
Mar 30 '25 |
Option Exercise |
0.00 |
9,330 |
0 |
9,330 |
| KOZY WILLIAM A | Director |
Mar 30 '25 |
Option Exercise |
0.00 |
1,034 |
0 |
28,496 |
| Hutchinson Michael Damon | Chief Legal Officer |
Mar 30 '25 |
Option Exercise |
0.00 |
2,930 |
0 |
6,686 |
| Shvartsburg Alex | Chief Financial Officer |
Mar 30 '25 |
Option Exercise |
0.00 |
11,083 |
0 |
30,196 |
| Poletti Franco | President, Cardiopulmonary |
Mar 30 '25 |
Option Exercise |
0.00 |
1,257 |
0 |
8,475 |
| Hutchinson Michael Damon | Chief Legal Officer |
Dec 15 '24 |
Option Exercise |
0.00 |
2,254 |
0 |
4,540 |
| Poletti Franco | President, Cardiopulmonary |
Dec 15 '24 |
Option Exercise |
0.00 |
967 |
0 |
7,634 |
| Barry James Christopher | Director |
Dec 15 '24 |
Option Exercise |
0.00 |
1,709 |
0 |
1,709 |
| Shvartsburg Alex | Chief Financial Officer |
Dec 15 '24 |
Option Exercise |
0.00 |
613 |
0 |
19,342 |
| Bianchi Francesco | Director |
Dec 11 '24 |
Sale |
50.99 |
1,250 |
63,738 |
7,522 |
0.56%
1.70%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):